New Belly-Delivered insulin put to the test in early trial
NCT ID NCT07341373
First seen Jan 17, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This early-stage study is testing a new concentrated insulin (U-500) given into the belly cavity in 25 adults with Type 1 Diabetes. The goal is to see if it is safe and how fast the body absorbs and uses it. Participants will have their blood sugar kept steady for 12 hours after a single dose to measure the drug's effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ProSciento, Inc.
RECRUITINGChula Vista, California, 91911, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.